RiVax®
Paper
A pilot clinical trial of a recombinant ricin vaccine in normal humans
Vitetta, E.S., et al., A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci U S A, 2006. 103(7): p. 2268-73.
Paper
Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin
Smallshaw, J.E., et al., Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine, 2005. 23(39): p. 4775-84.
Paper
Ricin poisoning: a comprehensive review
Audi, J., et al., Ricin poisoning: a comprehensive review. JAMA, 2005. 294(18): p. 2342-51.
Paper
Finding a new vaccine in the ricin protein fold
Olson, M.A., et al., Finding a new vaccine in the ricin protein fold. Protein Eng Des Sel, 2004. 17(4): p. 391-7.
Paper
The history of ricin, abrin and related toxins
Olsnes, S., The history of ricin, abrin and related toxins. Toxicon, 2004. 44(4): p. 361-70.
Paper
Improved stability of a protein vaccine through elimination of a partially unfolded state
McHugh, C.A., et al., Improved stability of a protein vaccine through elimination of a partially unfolded state. Protein Sci, 2004. 13(10): p. 2736-43.
Paper
Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence
Jefferson, T., M. Rudin, and C. Di Pietrantonj, Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence. Lancet Infect Dis, 2004. 4(2): p. 84-90.
Paper
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin’s lymphoma patients treated with an anti-CD25 immunotoxin
Castelletti, D., et al., A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. Clin Exp Immunol, 2004. 136(2): p. 365-72.
Paper
Immunological Characteristics Associated with the Protective Efficacy of Antibodies to Ricin
Maddaloni, M., et al., Immunological characteristics associated with the protective efficacy of antibodies to ricin. J. Immunol., 2004. 172(10): p. 6221-8.
Paper
A model for a smallpox-vaccination policy
Bozzette, S.A., et al., A model for a smallpox-vaccination policy. N Engl J Med, 2003. 348(5): p. 416-25.